Steroid-refractory acute graft-versus-host-disease (aGVHD) carries a poor prognosis. Daclizumab, a humanized monoclonal anti-interleukin-2 receptor antibody, has been tried in patients with steroid-refractory aGVHD, with the rationale that it may deplete allo-reactive T cells and modulate the severity of aGVHD while allowing a greater subsequent immunologic recovery than a nonselective pan-T-cell antibody. Reported outcomes, however, were conflicting. [1] [2] [3] [4] [5] We performed a retrospective review of the outcome of 12 consecutive allograft patients who had been treated with daclizumab for steroid-refractory (defined as X2 mg/kg per day of i.v. methylprednisolone for X3 days), grade III-IV aGVHD in our transplant unit. All patients had received standard GVHD prophylaxis using CYA and MTX (except patient 1 due to the absence of GVHD in a previous transplant). They were also given standard antimicrobial prophylaxis and pre-emptively monitored against CMV. Clinical grading of biopsy-confirmed aGVHD was performed according to standard criteria. Daclizumab was given at a dose of 1 mg/kg i.v. on days 1, 4, 8, 15 and 22. Treatment response at day 43 of aGVHD was defined according to Przepiorka et al. 1 (complete response if stage 0 achieved; partial response if a reduction in at least one stage in an organ without deterioration in the other organs).
The 12 allogeneic blood stem cell transplants consisted of nine siblings (seven ablative, two reduced-intensity) and three unrelated (one ablative, two reduced-intensity) allografts. There were six men and six women, with median age 38.5 years (range, 25-55). Acute GVHD occurred at a median of 27 days (range, 11-128); 25% of patients with skin, 50% with gut and 33% with liver involvement. Daclizumab was commenced after the failure of i.v. methylprednisolone at a median of 8 1 2 days (3-28). The responses to daclizumab therapy are shown in Table 1 . Typically, these patients also received numerous Although 58% of our patients survived at day 120, there was no long-term survivor, with infections as the main contributing terminal events in 10 of the 12 patients. In contrast to initial published reports, we found that allograft patients with severe steroid-refractory aGVHD in our institution had a poor response to daclizumab, resulting in a high incidence of infective complications and dismal outcome.
Comparison was made between our experience using daclizumab as salvage for steroid-refractory aGVHD, with those reported by others (Table 2) . [1] [2] [3] [4] Our results were a negative study in that the response rate was much lower than those reported by Przepiorka et al., 1 Srinivasan et al. 3 and Bordigoni et al. 4 On the contrary, Willenbacher et al. 2 also suggested similarly unfavourable long-term outcome and a high incidence of infectious complications including CMV.
Possible important factors contributing to the discrepanancies were: firstly, the severity of baseline aGVHD. Overall, it appeared that daclizumab might be useful in the early grades of aGVHD but limited activity in severe aGVHD. Secondly, the timing of the initiation of daclizumab: upfront vs early vs late salvage. Thirdly, it would be difficult to elucidate the independent role of daclizumab with the use of multiple immunosuppressants. Whereas, two previous studies had tried to wean patients off steroids 7 days after the start of daclizumab therapy, 1, 2 we were uncomfortable to do so due to the severity of the aGVHD in our patients. The concomitant use of corticosteroid was particularly worrisome, in the light of a recent, randomised controlled trial, which had demonstrated that the addition of daclizumab to corticosteroid as initial therapy for aGVHD did not improve aGVHD but was associated with significantly inferior survival. 5 As a result of this audit, we have moved away from the use of daclizumab and back to ATG as salvage aGVHD therapy. Novel prophylactic and therapeutic aGVHD therapies (recently reviewed in references 6, 7 ) are needed.
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